Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Infinity signs on AbbVie to help with late-stage cancer candidate duvelisib; deal ends

Executive Summary

Infinity Pharmaceuticals Inc. partnered its blood cancer candidate duvelisib (IPI145) with AbbVie Inc. Duvelisib, an oral phosphoinositide-3-kinase (PI3K)-delta/PI3K-gamma inhibitor, is currently in Phase II for indolent non-Hodgkin lymphoma (iNHL) and Phase III for chronic lymphocytic leukemia (CLL). The compound is also in Phase I for patients with advanced blood cancers.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register